KYMR — Kymera Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.99bn
- $8.30bn
- $39.21m
U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx
U.S. STOCKS ON THE MOVE-Xpeng, D-Wave Quantum, Trinity Biotech
Citigroup starts coverage of Kymera with $52 PT
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Microsoft
Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty
Kymera Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Kymera Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Kymera Plans To Initiate A KT-621 Phase 1B Trial In Atopic Dermatitis Patients In 2Q25 With Data In 4Q25
U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix
U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber
Kymera Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Kymera Therapeutics Announces Third Quarter 2024 Financial Results
Brief: Kymera Therapeutics Q3 EPS USD -0.82 Vs. IBES Estimate USD -0.84
U.S. RESEARCH ROUNDUP-Cintas, Nasdaq, Talen Energy
U.S. STOCKS ON THE MOVE-Medtronic, Texas Instruments, Fabrinet
U.S. STOCKS ON THE MOVE-Eli Lilly, Dentsply Sirona, Medtronic
U.S. STOCKS ON THE MOVE-Tesla, Bit Digital, Eli Lilly
U.S. STOCKS ON THE MOVE-Torrid Holdings, Treasure Global, Titan Pharmaceuticals
Kymera Therapeutics slips on pricing upsized $225 mln stock offering